Skip to content
Open access

Dual-functional bacterial extracellular vesicles with therapeutic oligonucleotides for synergistic treatment of ischemia/reperfusion injury in the brain.

Aug 2026 · Journal of Advanced Research · 0 citations · 31 references
Medicine

TL;DR

LpEVs may be useful for the treatment of ischemia/reperfusion injury with dual functions of its own anti-inflammatory effects and for delivery of therapeutic oligonucleotides.

Abstract

INTRODUCTION Ischemia/reperfusion (I/R) injury refers to secondary damage that occurs following ischemic stroke when reperfusion is achieved using thrombolytic agents. The abrupt restoration of blood flow induces excessive production of reactive oxygen species (ROS), inflammatory cytokines, and infiltration of immune cells, resulting in additional tissue injury. Although the anti-inflammatory effects of LpEVs have been researched, their potential as gene delivery vehicles has not been investigated.

Objectives

LpEV, which possesses anti-inflammatory properties and a lipid membrane structure, has the potential to be utilized as a gene delivery vehicle. Our study focuses on whether LpEVs act as delivery vehicles for anti-miRNA-181a oligonucleotides (AMO181a) and exert therapeutic effects on I/R injury.

Methods

LpEVs were isolated by PEG precipitation method. Physical characterization of LpEVs was performed by dynamic light scattering. In vitro cytokine assays were performed to evaluate the anti-inflammatory effect. For delivery of AMO181a, cholesterol-conjugated AMO181a (AMO181a-chol) was loaded into the LpEVs by hydrophobic interaction. Delivery efficiency of AMO181a was evaluated in Neuro2A cells by flow cytometry. The therapeutic effects of LpEVs and AMO181a were measured in the ischemia/reperfusion animal models.

Results

Anti-inflammatory effects of LpEVs were confirmed in the activated macrophages in vitro, reducing pro-inflammatory cytokines. Also, LpEVs decreased the infarct volume in an I/R animal model. Delivery efficiency of AMO181a-chol by LpEVs was higher than that of naked AMO181a-chol and comparable to the AMO181a-chol/polyethylenimine (25 kDa, PEI25k) complex in vitro and in vivo. Furthermore, LpEVs did not induce cytotoxicity. As a result, AMO181a-chol-loaded LpEVs had higher therapeutic effects than controls including LpEV alone, naked AMO181a-chol, and AMO181a-chol/PEI25k.

Conclusion

LpEVs may be useful for the treatment of ischemia/reperfusion injury with dual functions of its own anti-inflammatory effects and for delivery of therapeutic oligonucleotides.

Read PDF

Similar papers

Review Aug 2026

Chitosan Nanoparticles for the Treatment of Ischemia-Reperfusion Injury: Mechanisms, Preclinical Evidence, Challenges, and Future Perspectives.

Ischemia-reperfusion injury (IRI) is a complex pathological process involved in conditions such as organ transplantation, trauma, vascular surgery, myocardial infarction, and stroke. Although reperfusion is essential for restoring oxygen and nutrients to ischemic tissues, it can paradoxically worsen tissue damage throu...

Yongxin Dong, Wei-Dong Qiang · 0 citations
Review Open access Sep 2026

Pathophysiological Effects and Targeted Therapy Strategies of Neutrophil Extracellular Traps in Ischemia–Reperfusion Injury

Ischemia–reperfusion injury (IRI) is a common form of tissue injury encountered in myocardial infarction, ischemic stroke, solid-organ transplantation, and complex vascular surgery. Timely restoration of blood flow is essential for salvaging ischemic tissues; however, reperfusion itself can induce sterile inflammation...

Yan-Ning Lv, Lin-Wu Kuang, Zhi-Han Xiao et al. · 0 citations
Aug 2026

18β-Glycyrrhetinic Acid-Loaded ROS-Responsive Liposomes Enhance the Neuroprotective Efficacy against Cerebral Ischemic Stroke in Mice via a Microenvironment-Responsive Strategy

18β-Glycyrrhetinic acid (GA) exhibits excellent anti-inflammatory and antioxidant activities, and has attracted considerable attention in the field of cerebral ischemia−reperfusion (I/R) injury therapy. However, it is plagued by problems of low bioavailability and dose-dependent toxicity. As a drug delivery platform...

Yu Wang, Guan Wang, Xue-Nan Zhou et al. · 0 citations
Sep 2026

Thrombus-Targeted and Reactive Oxygen Species-Responsive Apigenin Liposomes for Ischemic Stroke.

Ischemic stroke remains a leading cause of mortality and long-term disability, while current therapies inadequately address oxidative stress, mitochondrial dysfunction, and blood-brain barrier (BBB) disruption during ischemia and reperfusion. Here, we developed DPCT@LIP-AP, a reactive oxygen species (ROS) responsive li...

Jing Guo, Meng-Na Li, Sihua Qi et al. · 0 citations
Open access Sep 2026

Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies

Myocardial ischemia–reperfusion injury (MIRI) is a critical pathological paradox following revascularization in acute myocardial infarction, yet effective clinical interventions remain limited. MIRI involves a complex, interlinked hierarchy of programmed cell death modalities, including ferroptosis, pyroptosis, and cup...

Dong Zhang, Xiao-Ting Yang, Sheng-Yu Gong et al. · 0 citations
Review Sep 2026

Therapeutic Targeting of IL-33 in Ischemia-Reperfusion Injury: Progress and Prospects.

Ischemia-Reperfusion Injury (IRI) is a prototypical sterile inflammatory process that complicates solid-organ transplantation, reperfusion therapy for acute myocardial infarction, and revascularization procedures. Clinical management relies largely on supportive and procedural measures; no specific targeted therapy is...

Dong-Heng Yang, Dai-Qiang Liu, Xi-Jian Ke et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.